Global trends demonstrate declining leukemia incidence in various age and sex groups, highlighting disparities.
e18547 Background: Leukemia remains a major contributor to the global cancer burden, with incidence patterns varying by age, sex, and sociodemographic development. Long-term, subgroup-specific global incidence trends have not been comprehensively characterized. Methods: We analyzed global leukemia incidence using Global Burden of Disease (GBD) 2023 estimates from 2000 to 2023. Incidence rates were expressed per 100,000 population with corresponding 95% confidence intervals (CIs). Temporal trends were evaluated using Joinpoint regression, estimating annual percent change (APC) and average annual percent change (AAPC) overall and stratified by sex, age group (<20, 20–54, >55 years), and Sociodemographic Index (SDI) categories. Results: Globally, leukemia incidence declined steadily from 2000 to 2023, with an overall AAPC of −1.08% (95% CI, −1.11% to −1.06%). By sex, incidence declined more steeply among females (AAPC −1.30%, 95% CI, −1.32% to −1.27%) than males (AAPC −0.93%, 95% CI, −0.96% to −0.90%). Across age groups, all strata experienced declining incidence, with the steepest reduction among adults aged 20–54 years (AAPC −1.13%, 95% CI, −1.17% to −1.09%), followed by individuals <20 years (AAPC −1.10%, 95% CI, −1.16% to −1.05%). Adults >55 years showed a sustained but comparatively slower decline (AAPC −1.01%, 95% CI, −1.04% to −0.97%). Across SDI strata, the largest long-term decline occurred in high SDI regions (AAPC −1.10%, 95% CI, −1.14% to −1.07%), while low SDI regions exhibited the slowest overall reduction (AAPC −0.46%, 95% CI, −0.50% to −0.43%), with periods of increase before recent declines. Conclusions: From 2000 to 2023, global leukemia incidence declined across all population subgroups. The slowest reductions were observed among males, adults aged >55 years, and populations in low SDI regions, highlighting persistent disparities despite overall downward trends.
No takes yet. Share an insight, caveat, or question.
Nabi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: